{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:54:41Z","timestamp":1791312881112,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monitoring mucosal inflammation is crucial to prevent complications and disease progression in Crohn\u2019s disease (CD). Endoscopy is the current standard, but is invasive. Clinical activity scores and non-invasive biochemical markers do not correlate well with mucosal inflammation. Microbial perturbations have been associated with disease activity in CD. Therefore, we aimed to investigate its potential use to differentiate CD patients in remission from those with an exacerbation. From 71 CD patients repeated fecal samples were collected, resulting in 97 active disease and 97 remission samples based on a combination of biochemical and clinical parameters. The microbiota composition was assessed by pyrosequencing of the 16S rRNA V1-V3 region. Random Forest analysis was used to find the most discriminatory panel of operational taxonomic units (OTUs) between active and remission samples. An independent internal validation set was used to validate the model. A combination of 50 OTUs was able to correctly predict 73% of remission and 79% of active samples with an AUC of 0.82 (sensitivity: 0.79, specificity: 0.73). This study demonstrates that fecal microbial profiles can be used to differentiate between active and remission CD and underline the potential of the fecal microbiota as a non-invasive tool to monitor disease activity in CD.<\/jats:p>","DOI":"10.1038\/srep35216","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T09:43:59Z","timestamp":1476351839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["The fecal microbiota as a biomarker for disease activity in Crohn\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Danyta. I.","family":"Tedjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Smolinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Savelkoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad A.","family":"Masclee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J.","family":"van Schooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.","family":"Pierik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Penders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy M. A. E.","family":"Jonkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"BFsrep35216_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ecco-jcc\/jjv039","volume":"9","author":"I Hilmi","year":"2015","unstructured":"Hilmi, I. et al. A First Study on the Incidence and Prevalence of IBD in Malaysia-Results From the Kinta Valley IBD Epidemiology Study. J. Crohns. Colitis 9, 404\u2013409 (2015).","journal-title":"J. Crohns. Colitis"},{"key":"BFsrep35216_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46\u201354.e42; quiz e30 (2012).","journal-title":"Gastroenterology"},{"key":"BFsrep35216_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart, D. C. & Sandborn, W. J. Crohn\u2019s disease. Lancet 380, 1590\u20131605 (2012).","journal-title":"Lancet"},{"key":"BFsrep35216_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bpg.2010.01.002","volume":"24","author":"A Stallmach","year":"2010","unstructured":"Stallmach, A., Hagel, S. & Bruns, T. Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24, 167\u2013182 (2010).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"BFsrep35216_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bpg.2009.10.011","volume":"24","author":"G Rogler","year":"2010","unstructured":"Rogler, G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24, 157\u2013165 (2010).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"BFsrep35216_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch, J., Jess, T., Martinato, M. & Lakatos, P. L. The burden of inflammatory bowel disease in Europe. J. Crohns. Colitis 7, 322\u2013337 (2013).","journal-title":"J. Crohns. Colitis"},{"key":"BFsrep35216_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/gut.2006.105577","volume":"56","author":"KR Palmer","year":"2007","unstructured":"Palmer, K. R. Complications of gastrointestinal endoscopy. Gut 56, 456\u2013457 (2007).","journal-title":"Gut"},{"key":"BFsrep35216_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/MIB.0000000000000341","volume":"21","author":"JD Falvey","year":"2015","unstructured":"Falvey, J. D. et al. Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission. Inflamm. Bowel Dis. 21, 824\u2013831 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire, S., Van Assche, G. & Rutgeerts, P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55, 426\u2013431 (2006).","journal-title":"Gut"},{"key":"BFsrep35216_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/00365521.2012.660542","volume":"47","author":"C-G af Bj\u00f6rkesten","year":"2012","unstructured":"af Bj\u00f6rkesten, C.-G. et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn\u2019s disease. Scand. J. Gastroenterol. 47, 528\u2013537 (2012).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFsrep35216_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","volume":"9","author":"C Manichanh","year":"2012","unstructured":"Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599\u2013608 (2012).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"BFsrep35216_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-014-0454-4","volume":"37","author":"K Matsuoka","year":"2015","unstructured":"Matsuoka, K. & Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 37, 47\u201355 (2015).","journal-title":"Semin. Immunopathol."},{"key":"BFsrep35216_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/MIB.0000000000000271","volume":"21","author":"EK Wright","year":"2015","unstructured":"Wright, E. K. et al. Recent advances in characterizing the gastrointestinal microbiome in Crohn\u2019s disease: a systematic review. Inflamm. Bowel Dis. 21, 1219\u20131228 (2015).","journal-title":"Bowel Dis."},{"key":"BFsrep35216_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jgh.12694","volume":"30","author":"P De Cruz","year":"2015","unstructured":"De Cruz, P. et al. Association between specific mucosa-associated microbiota in Crohn\u2019s disease at the time of resection and subsequent disease recurrence: a pilot study. J. Gastroenterol. Hepatol. 30, 268\u2013278 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFsrep35216_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut 55, 205\u2013211 (2006).","journal-title":"Gut"},{"key":"BFsrep35216_CR16","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1128\/JCM.00312-06","volume":"44","author":"PD Scanlan","year":"2006","unstructured":"Scanlan, P. D., Shanahan, F., O\u2019Mahony, C. & Marchesi, J. R. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn\u2019s disease. J. Clin. Microbiol. 44, 3980\u20133988 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep35216_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2036.2008.03860.x","volume":"29","author":"A Andoh","year":"2009","unstructured":"Andoh, A. et al. Faecal microbiota profile of Crohn\u2019s disease determined by terminal restriction fragment length polymorphism analysis. Aliment. Pharmacol. Ther. 29, 75\u201382 (2009).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep35216_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ibd.20903","volume":"15","author":"H Sokol","year":"2009","unstructured":"Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183\u20131189 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijmm.2007.07.016","volume":"298","author":"H Takaishi","year":"2008","unstructured":"Takaishi, H. et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol. 298, 463\u2013472 (2008).","journal-title":"Int. J. Med. Microbiol."},{"key":"BFsrep35216_CR20","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1128\/JCM.01360-10","volume":"48","author":"R Verma","year":"2010","unstructured":"Verma, R., Verma, A. K., Ahuja, V. & Paul, J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J. Clin. Microbiol. 48, 4279\u20134282 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep35216_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00535-010-0368-4","volume":"46","author":"A Andoh","year":"2011","unstructured":"Andoh, A. et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn\u2019s disease using terminal restriction fragment length polymorphism analysis. J. Gastroenterol. 46, 479\u2013486 (2011).","journal-title":"J. Gastroenterol."},{"key":"BFsrep35216_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00535-012-0605-0","volume":"47","author":"A Andoh","year":"2012","unstructured":"Andoh, A. et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn\u2019s disease. J. Gastroenterol. 47, 1298\u20131307 (2012).","journal-title":"J. Gastroenterol."},{"key":"BFsrep35216_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1128\/JCM.01500-13","volume":"52","author":"W Wang","year":"2014","unstructured":"Wang, W. et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 52, 398\u2013406 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep35216_CR24","doi-asserted-by":"publisher","first-page":"e90981","DOI":"10.1371\/journal.pone.0090981","volume":"9","author":"ES Wills","year":"2014","unstructured":"Wills, E. S. et al. Fecal microbial composition of ulcerative colitis and Crohn\u2019s disease patients in remission and subsequent exacerbation. PLoS One 9, e90981 (2014).","journal-title":"PLoS One"},{"key":"BFsrep35216_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gut.52.2.237","volume":"52","author":"P Seksik","year":"2003","unstructured":"Seksik, P. et al. Alterations of the dominant faecal bacterial groups in patients with Crohn\u2019s disease of the colon. Gut 52, 237\u2013242 (2003).","journal-title":"Gut"},{"key":"BFsrep35216_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1023\/B:DDAS.0000042241.13489.88","volume":"49","author":"C Basset","year":"2004","unstructured":"Basset, C., Holton, J., Bazeos, A., Vaira, D. & Bloom, S. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Dig. Dis. Sci. 49, 1425\u20131432 (2004).","journal-title":"Dig. Dis. Sci."},{"key":"BFsrep35216_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/1751-2980.12216","volume":"16","author":"JW Su","year":"2015","unstructured":"Su, J. W., Ma, J. J. & Zhang, H. J. Use of antibiotics in patients with Crohn\u2019s disease: a systematic review and meta-analysis. J. Dig. Dis. 16, 58\u201366 (2015).","journal-title":"J. Dig. Dis."},{"key":"BFsrep35216_CR28","doi-asserted-by":"publisher","first-page":"e39242","DOI":"10.1371\/journal.pone.0039242","volume":"7","author":"E Papa","year":"2012","unstructured":"Papa, E. et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One 7, e39242 (2012).","journal-title":"PLoS One"},{"key":"BFsrep35216_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","volume":"15","author":"D Gevers","year":"2014","unstructured":"Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn\u2019s disease. Cell Host Microbe 15, 382\u2013392 (2014).","journal-title":"Cell Host Microbe"},{"key":"BFsrep35216_CR30","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1128\/JCM.01004-06","volume":"44","author":"U Gophna","year":"2006","unstructured":"Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F. & Veldhuyzen van Zanten, S. J. O. Differences between tissue-associated intestinal microfloras of patients with Crohn\u2019s disease and ulcerative colitis. J. Clin. Microbiol. 44, 4136\u20134141 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep35216_CR31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/ajg.2012.335","volume":"107","author":"R Hansen","year":"2012","unstructured":"Hansen, R. et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn\u2019s but not in ulcerative colitis. Am. J. Gastroenterol. 107, 1913\u20131922 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"BFsrep35216_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","volume":"4","author":"G Van Assche","year":"2010","unstructured":"Van Assche, G. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Definitions and diagnosis. J. Crohns. Colitis 4, 7\u201327 (2010).","journal-title":"J. Crohns. Colitis"},{"key":"BFsrep35216_CR33","doi-asserted-by":"crossref","unstructured":"van den Heuvel, T. R. et al. Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL). Int. J. Epidemiol, doi: 10.1093\/ije\/dyv088 (2015).","DOI":"10.1093\/ije\/dyv088"},{"key":"BFsrep35216_CR34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1097\/MIB.0000000000000436","volume":"21","author":"AGL Bodelier","year":"2015","unstructured":"Bodelier, A. G. L. et al. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn\u2019s Disease: A Metabolomic Approach. Inflamm. Bowel Dis. 21, 1776\u20131785 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR35","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218\u20132224 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/01621459.1988.10478575","volume":"83","author":"JB Burbidge","year":"1988","unstructured":"Burbidge, J. B., Magee, L. & Robb, A. L. Alternative Transformations to Handle Extreme Values of the Dependent Variable. J. Am. Stat. Assoc. 83, 123 (1988).","journal-title":"J. Am. Stat. Assoc."},{"key":"BFsrep35216_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.7326\/0003-4819-110-11-916","volume":"110","author":"DF Williamson","year":"1989","unstructured":"Williamson, D. F., Parker, R. A. & Kendrick, J. S. The box plot: a simple visual method to interpret data. Ann. Intern. Med. 110, 916\u2013921 (1989).","journal-title":"Ann. Intern. Med."},{"key":"BFsrep35216_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2015.06.042","volume":"899","author":"J Engel","year":"2015","unstructured":"Engel, J. et al. Regularized MANOVA (rMANOVA) in untargeted metabolomics. Anal. Chim. Acta 899, 1\u201312 (2015).","journal-title":"Anal. Chim. Acta"},{"key":"BFsrep35216_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gut.52.2.237","volume":"52","author":"P Seksik","year":"2003","unstructured":"Seksik, P. et al. Alterations of the dominant faecal bacterial groups in patients with Crohn\u2019s disease of the colon. Gut 52, 237\u2013242 (2003).","journal-title":"Gut"},{"key":"BFsrep35216_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ajg.2015.149","volume":"110","author":"K-L Kolho","year":"2015","unstructured":"Kolho, K.-L. et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. Am. J. Gastroenterol. 110, 921\u2013930 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"BFsrep35216_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1574-6976.2010.00251.x","volume":"35","author":"D Knights","year":"2011","unstructured":"Knights, D., Costello, E. K. & Knight, R. Supervised classification of human microbiota. FEMS Microbiol. Rev. 35, 343\u2013359 (2011).","journal-title":"FEMS Microbiol. Rev."},{"key":"BFsrep35216_CR42","doi-asserted-by":"crossref","unstructured":"David, B. et al. Anti-TNF treatment with adalimumab induces changes in the microbiota of Crohn\u2019s disease. J. Crohns. Colitis jjv119 doi: 10.1093\/ecco-jcc\/jjv119 (2015).","DOI":"10.1093\/ecco-jcc\/jjv119"},{"key":"BFsrep35216_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2036.2011.04732.x","volume":"34","author":"CN Andrews","year":"2011","unstructured":"Andrews, C. N. et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 34, 374\u2013383 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep35216_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11306-009-0185-z","volume":"6","author":"JA Westerhuis","year":"2010","unstructured":"Westerhuis, J. A., van Velzen, E. J. J., Hoefsloot, H. C. J. & Smilde, A. K. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics 6, 119\u2013128 (2010).","journal-title":"Metabolomics"},{"key":"BFsrep35216_CR45","doi-asserted-by":"publisher","first-page":"e7087","DOI":"10.1371\/journal.pone.0007087","volume":"4","author":"YV Karpievitch","year":"2009","unstructured":"Karpievitch, Y. V., Hill, E. G., Leclerc, A. P., Dabney, A. R. & Almeida, J. S. An introspective comparison of random forest-based classifiers for the analysis of cluster-correlated data by way of RF++. PLoS One 4, e7087 (2009).","journal-title":"PLoS One"},{"key":"BFsrep35216_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00180-011-0249-1","volume":"26","author":"W Adler","year":"2011","unstructured":"Adler, W., Potapov, S. & Lausen, B. Classification of repeated measurements data using tree-based ensemble methods. Comput. Stat. 26, 355\u2013369 (2011).","journal-title":"Comput. Stat."},{"key":"BFsrep35216_CR47","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.3748\/wjg.v19.i22.3404","volume":"19","author":"R Kumari","year":"2013","unstructured":"Kumari, R., Ahuja, V. & Paul, J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J. Gastroenterol. 19, 3404\u20133414 (2013).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep35216_CR48","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/ibd.21923","volume":"18","author":"Y D\u00f6rffel","year":"2012","unstructured":"D\u00f6rffel, Y., Swidsinski, A., Loening-Baucke, V., Wiedenmann, B. & Pavel, M. Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn\u2019s disease and the effect of therapy. Inflamm. Bowel Dis. 18, 1663\u20131671 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","volume":"63","author":"K Machiels","year":"2014","unstructured":"Machiels, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275\u20131283 (2014).","journal-title":"Gut"},{"key":"BFsrep35216_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ibd.20330","volume":"14","author":"A Swidsinski","year":"2008","unstructured":"Swidsinski, A., Loening-Baucke, V., Vaneechoutte, M. & Doerffel, Y. Active Crohn\u2019s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm. Bowel Dis. 14, 147\u2013161 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/apt.12365","volume":"38","author":"E Varela","year":"2013","unstructured":"Varela, E. et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 38, 151\u2013161 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep35216_CR52","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1574-6941.2011.01252.x","volume":"79","author":"J Vermeiren","year":"2012","unstructured":"Vermeiren, J. et al. Decreased colonization of fecal Clostridium coccoides\/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol. Ecol. 79, 685\u2013696 (2012).","journal-title":"FEMS Microbiol. Ecol."},{"key":"BFsrep35216_CR53","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1128\/JCM.01500-13","volume":"52","author":"W Wang","year":"2014","unstructured":"Wang, W. et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 52, 398\u2013406 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep35216_CR54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ibd.20783","volume":"15","author":"B Willing","year":"2009","unstructured":"Willing, B. et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn\u2019s disease. Inflamm. Bowel Dis. 15, 653\u2013660 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep35216_CR55","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00535-012-0605-0","volume":"47","author":"A Andoh","year":"2012","unstructured":"Andoh, A. et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn\u2019s disease. J. Gastroenterol. 47, 1298\u20131307 (2012).","journal-title":"J. Gastroenterol."},{"key":"BFsrep35216_CR56","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731\u201316736 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep35216_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2180-11-7","volume":"11","author":"AW Walker","year":"2011","unstructured":"Walker, A. W. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11, 7 (2011).","journal-title":"BMC Microbiol."},{"key":"BFsrep35216_CR58","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731\u201316736 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep35216_CR59","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3201\/eid0602.000210","volume":"6","author":"TP Prindiville","year":"2000","unstructured":"Prindiville, T. P. et al. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. 6, 171\u2013174 (2000).","journal-title":"Emerg. Infect. Dis."},{"key":"BFsrep35216_CR60","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/gast.1996.v110.pm8613048","volume":"110","author":"CL Wells","year":"1996","unstructured":"Wells, C. L. et al. Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology 110, 1429\u20131437 (1996).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep35216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35216","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:44:02Z","timestamp":1672886642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep35216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep35216"],"URL":"https:\/\/doi.org\/10.1038\/srep35216","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]},"assertion":[{"value":"18 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Masclee receives grants from DSM, Grunenthal, Abbott and Danone. M. Pierik acted as a consultant for Takeda in the past, is a former lecturer for Abbvie, Falk, MSD and Ferring. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35216"}}